Claims for Patent: 9,670,281

Summary for Patent: 9,670,281

Title:	Binding-triggered transcriptional switches and methods of use thereof
Abstract:	The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.
Inventor(s):	Lim; Wendell A. (San Francisco, CA), Morsut; Leonardo (San Francisco, CA), Roybal; Kole T. (San Francisco, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	15/096,971
Patent Claims:	1. An isolated nucleic acid comprising a nucleotide sequence encoding a chimeric Notch polypeptide comprising, from N-terminal to C-terminal and in covalent linkage: a) an extracellular domain comprising a single-chain Fv (scFv) or a nanobody that specifically binds to an antigen; b) a Notch regulatory region comprising a Lin 12-Notch repeat, a heterodimerization domain comprising an S2 proteolytic cleavage site and a transmembrane domain comprising an S3 proteolytic cleavage site; and c) an intracellular domain, heterologous to the Notch regulatory region, comprising a transcriptional activator comprising a DNA binding domain, wherein the transcriptional activator replaces a naturally-occurring intracellular notch domain, and wherein binding of the scFv or the nanobody to the antigen in trans induces cleavage at the S2 and S3 proteolytic cleavage sites, thereby releasing the intracellular domain and wherein the chimeric Notch polypeptide does not bind its naturally-occurring ligand Delta. 2. The isolated nucleic acid of claim 1, wherein release of the intracellular domain causes the transcriptional activator to induce expression of an endogenous gene product in a cell comprising the nucleic acid. 3. The isolated nucleic acid of claim 1, wherein release of the intracellular domain causes the transcriptional activator to induce expression of a heterologous gene product in a cell comprising the nucleic acid. 4. The isolated nucleic acid of claim 1, wherein the nucleic acid further comprises a transcriptional control element, responsive to the transcriptional activator, operably linked to a nucleotide sequence encoding a chimeric antigen receptor (CAR). 5. The isolated nucleic acid of claim 1, wherein the nucleic acid further comprises a transcriptional control element, responsive to the transcriptional activator, operably linked to a nucleotide sequence encoding a therapeutic antibody for the treatment of cancer. 6. The isolated nucleic acid of claim 5, wherein the therapeutic antibody for the treatment of cancer is selected from pembrolizumab and tremelimumab. 7. The isolated nucleic acid of claim 1, wherein the Notch regulatory region has at least 85% amino acid sequence identity to any one of the Notch regulatory regions of SEQ ID NO:131, 132 and 135-137. 8. The isolated nucleic acid of claim 1, wherein the Notch regulatory region further comprises, at its N-terminus, one or more epidermal growth factor (EGF) repeats. 9. The isolated nucleic acid of claim 8, wherein the Notch regulatory region comprises, at its N-terminus, 2 to 11 EGF repeats. 10. The isolated nucleic acid of claim 1, wherein the chimeric Notch polypeptide comprises a synthetic linker. 11. The isolated nucleic acid of claim 8, wherein the chimeric Notch polypeptide comprises a synthetic linker between the one or more EGF repeats. 12. The isolated nucleic acid of claim 1, wherein the antigen is a cancer-associated antigen. 13. The isolated nucleic acid of claim 1, wherein the S2 proteolytic cleavage site is an ADAM-17-type protease cleavage site comprising an Ala-Val dipeptide sequence. 14. The isolated nucleic acid of claim 1, wherein the S3 proteolytic cleavage site is a gamma-secretase (.gamma.-secretase) cleavage site comprising a Gly-Val dipeptide sequence. 15. The isolated nucleic acid of claim 1, wherein the chimeric Notch polypeptide further comprises an S1 proteolytic cleavage site. 16. The isolated nucleic acid of claim 15, wherein the S1 proteolytic cleavage site is a furin-like protease cleavage site comprising the amino acid sequence Arg-X-(Arg/Lys)-Arg, where X is any amino acid. 17. The isolated nucleic acid of claim 1, wherein the chimeric Notch polypeptide lacks an S1 proteolytic cleavage site. 18. A recombinant expression vector comprising the nucleic acid of claim 1. 19. The recombinant expression vector of claim 18, wherein the recombinant expression vector further comprises a transcriptional control element, responsive to the transcriptional activator, operably linked to a nucleotide sequence encoding a chimeric antigen receptor (CAR). 20. The recombinant expression vector of claim 18, wherein the recombinant expression vector further comprises a transcriptional control element, responsive to the transcriptional activator, operably linked to a nucleotide sequence encoding a therapeutic antibody for the treatment of cancer. 21. A cell genetically modified cell comprising the nucleic acid of claim 1. 22. The cell of claim 21, wherein the cell is selected from the group consisting of: an immune cell, a neuron, an epithelial cell, an endothelial cell, or a stem cell. 23. The cell of claim 22, wherein the immune cell is selected from the group consisting of: a T cell, a B cell, a monocyte, a natural killer cell, a dendritic cell, a macrophage, a regulatory T cell, a helper T cell, or a cytotoxic T cell. 24. The cell of claim 23, wherein the immune cell is a T cell.

Details for Patent 9,670,281

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2035-02-24
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2035-02-24